See more : Vodafone Group Public Limited Company (VOD.L) Income Statement Analysis – Financial Results
Complete financial analysis of Cortexyme, Inc. (CRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cortexyme, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nuvus Gro Corp. (NUVG) Income Statement Analysis – Financial Results
- Excite Holdings Co., Ltd. (5571.T) Income Statement Analysis – Financial Results
- Meta Platforms, Inc. (META) Income Statement Analysis – Financial Results
- Dalmia Bharat Sugar and Industries Limited (DALMIASUG.BO) Income Statement Analysis – Financial Results
- HBM Holdings Limited (2142.HK) Income Statement Analysis – Financial Results
Cortexyme, Inc. (CRTX)
About Cortexyme, Inc.
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 60.80M | 61.31M | 30.21M | 10.09M | 9.10M |
| General & Administrative | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Cost & Expenses | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Interest Income | 620.00K | 2.04M | 2.19M | 806.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 957.00K | 1.64M |
| Depreciation & Amortization | 344.00K | 332.00K | 188.00K | 51.00K | 45.00K |
| EBITDA | -90.32M | -78.89M | -39.17M | -11.47M | -10.55M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -89.95M | -78.89M | -39.17M | -12.12M | -10.37M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 373.00K | 2.04M | 2.19M | -357.00K | -1.87M |
| Income Before Tax | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 373.00K | 2.04M | 2.19M | 600.00K | -222.00K |
| Net Income | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.02 | -2.63 | -1.94 | -0.58 | -0.57 |
| EPS Diluted | -3.02 | -2.63 | -1.94 | -0.58 | -0.57 |
| Weighted Avg Shares Out | 29.77M | 29.18M | 19.06M | 21.55M | 21.55M |
| Weighted Avg Shares Out (Dil) | 29.77M | 29.18M | 19.06M | 21.55M | 21.55M |
CRTX Stock: What to Know as Cortexyme Plummets 75%
Today, investors in CRTX stock lament a rather poor announcement from the company that a key clinical trial missed its primary endpoint. The post CRTX Stock: What to Know as Cortexyme Plummets 75% appeared first on InvestorPlace.
Why Cortexyme Shares Are Falling
Cortexyme Inc (NASDAQ: CRTX) shares are trading lower after the company's Phase 2/3 GAIN trial did not meet its co-primary endpoints. Cortexyme says they will present the additional top-line results from the GAIN Trial at the upcoming 14th Clinical Trials on...
Here's Why Cortexyme Is Imploding on Wednesday
An Alzheimer's disease trial failure was much worse than the company's relatively upbeat look forward suggests.
Cortexyme's stock tumbles on failed clinical trial for Alzheimer's drug
Shares of Cortexyme Inc. CRTX, -73.76% tumbled 72.7% in trading on Wednesday, the day after the company said a late-stage clinical trial evaluating its experimental Alzheimer's disease treatment failed to meet the study's endpoints. Cortexyme's stock is down 43.3% this...
Why Cortexyme Shares Are Plunging 70% After Hours
Shares of a clinical-stage biopharmaceutical company are falling in after-hours trading Tuesday after the company shared an update. What Happened: Cortexyme Inc (NASDAQ: CRTX) reported Phase 2/3 GAIN trial data for its Alzheimer's disease trial Tuesday.
Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX) today reported top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (COR388), an investigational orally administered small-molecule that targets gingipain proteases from the bacterium...
SA Interview: Investing In The Pharmaceutical Industry With Small Pharma Analyst
Small Pharma Analyst is a veteran of the pharma industry and specializes in the analysis of small pharma companies. The opportunity in small-caps, leveraging their industry experience to gain an edge and how to find catalysts are topics discussed.
Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease
Cortexyme has a unique hypothesis- that Alzheimer's disease (AD) is caused by a neurological infection with P. gingivalis. There is a surprising amount of data generated by the company and independent labs supporting this hypothesis.
Cortexyme: Alzheimer's Readout In November A Binary Event
CRTX is pursuing a highly speculative hypothesis that gingivitis plays a role in the pathogenesis of Alzheimer's Disease (AD). Top line results for AD Phase 2/3 trial expected mid-November; success would be one of the greatest medical breakthroughs in modern...
Cortexyme: Shifting The Odds In Your Favor So Your Best Case Outcome Is Three Times Higher Than Your Worst Case
Screen capture via Cortexyme animation. A Bigger Bubble Than The Late '90s
Source: https://incomestatements.info
Category: Stock Reports